Certara (CERT) to Release Quarterly Earnings on Thursday

Certara (NASDAQ:CERT) is expected to post its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Certara to post earnings of $0.12 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Certara Price Performance

Certara stock opened at $11.85 on Wednesday. The stock has a 50-day moving average price of $12.50 and a two-hundred day moving average price of $11.63. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a market capitalization of $1.91 billion, a PE ratio of -59.25, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CERT shares. TD Cowen started coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective for the company. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Barclays increased their price objective on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.